Related Experiment Video

Updated: May 31, 2026

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines
05:39

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters

Giovanni N Berta1, Andrea E Sprio, Manuela Iezzi

  • 1Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. giovanni.berta@unito.it

Cancer Prevention Research (Philadelphia, Pa.)
|July 8, 2011
PubMed

Insights

Vaccines targeting the ERBB2 oncoantigen show promise in preventing chemical-induced oral cancer. DNA vaccinations against ERBB2 reduced oral lesions in hamsters, supporting vaccines for managing exposure to carcinogens.

Area of Science:

  • Oncology
  • Immunology
  • Carcinogenesis

Background:

  • Chemical mutagens cause a significant percentage of human cancers.
  • Vaccines targeting oncoantigens have shown success in preventing early neoplastic lesions in mouse models.
  • The efficacy of oncoantigen vaccines in preventing chemical carcinogenesis remains unexplored.

Purpose of the Study:

  • To investigate the potential of vaccines against the oncoantigen ERBB2 in preventing chemical carcinogenesis.
  • To explore the role of ERBB2 overexpression in 7,12-dimethylbenz[α]anthracene (DMBA)-induced oral carcinogenesis.
  • To assess the impact of anti-ERBB2 vaccination on the development of oral lesions.

Main Methods:

  • Utilized Syrian hamsters as a model for DMBA-induced oral carcinogenesis.
  • Administered repeated DNA vaccinations targeting the ERBB2 oncoantigen.
  • Quantified the number, size, and severity of oral lesions.
  • Measured the anti-ERBB2 antibody response.

Main Results:

  • ERBB2 was transiently overexpressed during early stages of DMBA-induced oral carcinogenesis.
  • Repeated DNA vaccinations against ERBB2 significantly reduced oral lesions.
  • The reduction in lesion development was directly proportional to the anti-ERBB2 antibody response.

Conclusions:

  • Vaccines targeting ERBB2 can prevent chemical carcinogenesis-induced oral lesions.
  • Anti-ERBB2 vaccination represents a potential strategy for managing individuals at risk of exposure to carcinogenic agents.
  • This study highlights a novel therapeutic approach for cancer prevention.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex06:12

Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex

Published on: January 9, 2018

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...